Ariceum and Eckert & Ziegler sign deal for cancer-treating radionuclides, advancing precision treatments.
Ariceum Therapeutics and Eckert & Ziegler have signed a global supply agreement for medical radionuclides used in treating hard-to-treat cancers. Eckert & Ziegler will supply Ariceum with Actinium-225 and Lutetium-177 for clinical studies and future commercial phases. The agreement supports the development of precision cancer treatments, with options for expanding to other drugs and radionuclides.
4 months ago
3 Articles
Further Reading
You have 3 free stories remaining this month. Subscribe anytime for unlimited access.